Immunogenicity in Infants of a Vaccine Composed of Haemophilus Influenza Type b Capsular Polysaccharide Mixed with dpt or Conjugated to Diphtheria Toxoid

Journal of Infectious Diseases

Volumn 155, Issue 1, 1987, Pages 100-106

  Käyhty, Helena ^a,b,c,d   Eskola, Juhani ^a,b,c,d   Peltola, Heikki ^a,b,c,d   Stout, Mason G ^a,b,c,d   Samuelson, Joel S ^a,b,c,d   Gordon, Lance K ^a,b,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b WYETH RESEARCH   (United States)

^c Connaught Laboratories ^*  (United States)

^d Connaught Research Institute ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; VACCINE;

ANTIBODY RESPONSE; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; NORMAL HUMAN; PREVENTION; PRIORITY JOURNAL;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG COMBINATIONS; EVALUATION STUDIES; HAEMOPHILUS VACCINES; HUMANS; INFANT; PERTUSSIS VACCINE; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID;

EID: 0023103961     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/155.1.100     Document Type: Article

References (32)

1. Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus injluenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory. Pediatrics 1984;74:857-65
2. Smith DH, Peter G, Ingram DL, Harding AL, Anderson P. Responses of children immunized with the capsular polysaccharide of Hemophilus injluenzae, type b. Pediatrics 1973;52:637-44
3. Robbins JB, Schneerson R, Argaman M, Handzel ZT. Haemophilus injluenzae type b: Disease and immunity in humans. Ann Intern Med 1973;78:259-69
4. Parke JC Jr, Schneerson R, Robbins JB, Schlesselman JJ Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg County, North Carolina (March 1974-March 1976). J Infect Dis 1977;136:S51-6
5. Peltola H, Käyhty H, Virtanen M, Mäkelä PH. Prevention of Hemophilus injluenzae type Bbacteremic infections with the capsular polysaccharide vaccine. New Engl J Med 1984;310:1561-6
6. Cochi SL, Broome CV Vaccine prevention of Haemophilus injluenzae type b disease: Past, present and future. Pediatr Infect Dis 1986;5:12-9
7. Coulehan JL, Hallowell C, Michaels RH, Welty TK, Lui N, Kuo JSC. Immunogenicity of a Haemophilus injluenzae type b vaccine in combination with diphtheria-pertussistetanus vaccine in infants. J Infect Dis 1983;148:530-4
8. Schneerson R, Barrera O, Sutton A, Robbins JB. Preparation, characterization, and immunogenicity of HaemophiIus injluenzae type b polysaccharide-protein conjugates. J Exp Med 1980;152:361-76
9. Anderson P. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197. Infect Immun 1983;39:233-8
10. Gold R, Lepow ML, Goldschneider I, Draper TF, Gotschlich EC. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: Prospects for routine immunization of infants and children. J Infect Dis 1979;140:690-7
11. Koskela M, Leinonen M, Häivä VM, Timonen M, Mäkelä PH. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986;5:45-50
12. King SD, Ramlal A, Wynter H, Moodie K, Castle D, Kuo JSC, Barnes L, Williams CL. Safety and immunogenicity of a new Haemophilus injluenzae type b vaccine in infants under one year of age. Lancet 1981;2:705-9
13. Lepow ML, Peter G, Glode MP, Daum RS, Calnen G, Knight KM, Mayer D, Kuo JSC, Lui NST. Response of infants to Haemophilus injluenzae type b polysaccharide and diphtheria-tetanus-pertussis vaccines in combination. J Infect Dis 1984;149:950-5
14. Pincus DJ, Morrison D, Andrews C, Lawrence E, Sell SH, Wright PF. Age-related response to two Haemophilus injluenzae type b vaccines. J Pediatr 1982;100:197-201
15. Granoff OM, Boies EG, Munson RS Jr. Immunogenicity of Haemophilus injluenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in adults. J Pediatr 1984; 105:22-7
16. Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus injluenzae type b polysaccharide- diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. J Pediatr 1985;106:185-9
17. Lepow ML, Samuelson JS, Gordon LK. Safety and immunogenicity of Haemophilus injluenzae type b polysaccharide- diphtheria toxoid conjugate vaccine in adults. J Infect Dis 1984;150:402-6
18. Eskola J, Käyhty H, Peltola H, Karanko V, Mäkelä PH, Samuelson J, Gordon LK. Antibody levels achieved in infants by course of Haemophilus injluenzae type B polysaccharide/diphtheria toxoid conjugate vaccine. Lancet 1985;1:1184-6
19. Anderson P, Pichichero ME, Insel RA. Immunogens consisting of oligosaccharides from the capsule of HaemophiIus injluenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest 1985;76:52-9
20. Schneerson R, Robbins JB, Chu C, Sutton A, Vann W, Vickers JC, London WT, Curfman B, Hardegree MC, Shiloach J, Rastogi SC. Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus injluenzae type b and pneumococcus type 6A capsular polysaccharide- protein conjugates. Infect Immun 1984;45: 582-91
21. Weinberg GA, Einhorn M, Granoff PO, Granoff OM. Safety and immunogenicity of a new Haemophilus injluenzae type b (Hib) polysaccharide-outer membrane protein (PS-OMP) conjugate vaccine [abstract 279]. In: Program and abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1985
22. Gordon LK. Haemophilus injluenzae b polysaccharide ex otoxoid conjugate vaccine. Patent 83/4939. Republic of South Africa, 1984
23. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of “natural” and immunizationinduced Haemophilus injluenzae type b capsular polysaccharide antibodies. Pediatr Res 1973;7:103-10
24. Mäkelä PH, Peltola H, Käyhty H, Jousimies H, Pettay O, Ruoslahti E, Sivonen A, Renkonen O-V. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus injluenzae type b: A field trial in Finland. J Infect Dis 1977;136:S43-50
25. Gray BM. ELISA methodology for polysaccharide antigens: Protein coupling of polysaccharides for adsorption to plastic tubes. J Immunol Methods 1979;28:187-92
26. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus injluenzae type b. J Infect Dis 1983;147:1100
27. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus injluenzae type b. J Infect Dis 1984;149:1034
28. Barkin RM, Pichichero ME. Diphtheria-pertussis-tetanus vaccine: Reactogenicity of commercial products. Pediatrics 1979;63:256-60
29. Moxon ER, Anderson P, Smith DH, Adrianzen TB, Graham GG, Baker RS. Antibody responses to a combination vaccine against Haemophilus injluenzae type b, diphtheria, pertussis, and tetanus. Bull WHO 1975;52:87-90
30. Ambrosino DM, Glode MP, Williams CL, Siber GR. Antibody response of infants to Haemophilus influenzae type b capsular polysaccharide combined with Bordetella pertussis. J Infect Dis 1985;151:1174
31. Kuo JSC, Monji N, McCoy DW. Development of Haemophilus influenzae type b vaccine: A combined vaccine consisting of the capsular polysaccharide, polyribosyl ribitol, phosphate, and Bordetella pertussis. In: Sell SH, Wright PF, eds. Haemophilus injluenzae, epidemiology, immunology, and prevention of disease. New York: Elsevier, 1982:243-53
32. Käyhty H, Schneerson R, Sutton A. Class-specific antibody response to Haemophilus injluenzae type b capsular polysaccharide vaccine. J Infect Dis 1983;148:767